The functional human immune system, including T, B, and natural killer lymphocytes, is reconstituted in NOD/ Shi-scid/IL-2R␥ null (NOG) mice that receive hematopoietic stem cell transplants. Here, we show that these humanized mice can recapitulate key aspects of Epstein-Barr virus (EBV) infection in humans. Inoculation with ϳ1 ؋ 10 3 TD 50 (50% transforming dose) of EBV caused B cell lymphoproliferative disorder, with histopathological findings and latent EBV gene expression remarkably similar to that in immunocompromised patients. Inoculation with a low dose of virus (Ϲ1 ؋ 10 1 TD 50 ), in contrast, resulted in apparently asymptomatic persistent infection. Levels of activated CD8
Epstein-Barr virus (EBV) is a tumor virus associated with a variety of malignancies, including Burkitt lymphoma, nasopharyngeal carcinoma, and Hodgkin lymphoma [1] . It is also an etiological agent of infectious mononucleosis (IM), which is characterized by transient proliferation of EBV-infected B lymphoblastoid cells and an excessive anti-EBV T cell response. EBV has a unique ability to growth transform human B lymphocytes in vitro and establish lymphoblastoid cell lines (LCLs) [2] . EBV-transformed lymphoblasts express 6 nuclear proteins (Epstein-Barr nuclear antigen [EBNA] 1, 2, 3A, 3B, 3C, and LP) and 3 membrane proteins (latent membrane protein [LMP] 1, 2A, and 2B), and this pattern of EBV gene expression is termed latency III. In contrast, Burkitt lymphoma cells express only EBNA1 consistently (latency I), whereas Hodgkin lymphoma and nasopharyngeal carcinoma cells express EBNA1, LMP1, and LMP2 (latency II). In vivo, EBV-transformed cells are effectively removed by virus-specific cytotoxic T cells, and EBV infection in immunocompetent humans is usually subclinical, except for IM caused by primary infection during adolescence or adulthood. However, in immunocompromised hosts, such as patients with AIDS and transplant recipients, EBV-infected B lymphoblasts can proliferate and cause lymphoproliferative disorder.
EBV infects only humans in nature and limited animal species under experimental conditions. It can infect cotton-top tamarins and induce lymphomas, which have been used as a model of EBV-associated lymphomas [3, 4] . Nonhuman primates possess their own lymphocryptoviruses related to EBV, and research on the use of these virus-host systems as models of EBV infection is currently in progress [5, 6] . Small-animal models of EBV have also been developed, which are particularly useful when a large number of animals are necessary. Scid mice that receive intraperitoneal transplants of EBV-transformed LCLs or peripheral blood mononuclear cells (PBMCs) isolated from EBV-infected persons develop lymphomas, which have been used as a model of human lymphoproliferative disorder [7] [8] [9] . Recently, NOD/ scid mice transplanted with human hematopoietic stem cells (HSCs) and reconstituted mainly with B lymphocytes were infected with EBV, and the development of lymphoproliferative disorder was described [10] . The immune response to EBV was not studied in these scid or NOD/scid mouse models. Very recently, a functional human immune system could be reconstituted in highly immunodeficient mouse strains, and these socalled humanized mice were shown able to mount an EBVspecific T cell response [11, 12] . These studies were, however, performed mainly using immunological standpoints and did not provide detailed virological data.
NOD/Shi-scid/IL-2R␥ null (referred to here as NOG) is a highly immunodeficient mouse strain that was developed very recently and that, after transplantation with cord blood HSCs, is able to reconstitute most major components of the hematolymphoid system, including T cells, B cells, NK cells, macrophages, and dendritic cells [13] [14] [15] . Human T cells that develop in NOG mice are functional in that they can be activated to display cytotoxic activity [15, 16] . These properties made NOG mice an excellent model of human virus infections targeting the immune system, such as those with human T-lymphotropic virus-1 and HIV-1 [17] [18] [19] [20] . Here, we provide evidence that humanized NOG mice can reproduce various key aspects of human EBV infection and propose that they may be a valuable tool for studies of EBV infection.
METHODS
Preparation of humanized mice. NOG mice were obtained from the Central Institute for Experimental Animals (Kawasaki, Japan). Protocols for experiments with NOG mice were approved by the Institutional Animal Care and Use Committee of the National Institute of Infectious Diseases (NIID). Cord blood was supplied by the Tokyo Cord Blood Bank after obtaining informed consent. The use of human materials in this research was approved by the institutional review boards of the National Research Institute for Child Health and Development, the NIID, the Tokyo Medical and Dental University, and the Tokyo Cord Blood Bank. The isolation of human CD34
ϩ HSCs from cord blood by means of the MACS Direct CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec), their intravenous injection (1 ϫ 10 4 to 1.2 ϫ 10 5 cells/mouse) into 6 -10-week-old female NOG mice, and the characterization of the reconstitution of the human hematoimmune system were done as described elsewhere [18, 20] . NOG mice in which the human hematoimmune system was reconstituted are referred here as humanized NOG (hNOG) mice.
Experimental EBV infection, quantification of viral DNA, and detection of viral mRNAs. Virus production by EBVinfected Akata cells was stimulated by brief treatment with antiIgG antibody (Dako), and culture fluid was used as inoculum after filtration through a 0.45-m membrane filter [21] . For virus titration, cord blood lymphocytes were plated at the density of 2 ϫ 10 5 cells per well in 6-well plates and then inoculated with serial 10-fold dilutions of virus preparation. The number of wells with proliferating lymphocytes was counted 6 weeks after infection, and the titer of the virus in 50% transforming dose (TD 50 ) was determined by the Reed-Muench method [22] . EBV was inoculated intravenously through the tail vein. EBV DNA was quantified by a real-time quantitative polymerase chain reaction (PCR) assay based on the TaqMan system (Applied Biosystems), as described elsewhere [23] . Analysis of EBV gene expression by reverse-transcription PCR (RT-PCR) was done as described elsewhere, using the primers listed in table 1 [24] .
Histopathology, in situ hybridization (ISH), and immunohistochemistry. Tissue samples were fixed in 10% buffered formalin, embedded in paraffin, and stained with hematoxylineosin. For phenotypic analysis of proliferating lymphocytes, immunostaining for CD3 (Nichirei), CD4 (Novocastra), CD8 (Nichirei), CD45RO, CD20, CD79a, CD30, Mum1 (Dako), CD23, CD10, CD56 (Novocastra), granzyme B (Dako), and T cell intracellular antigen 1 (Beckman Coulter) was performed on paraffin sections. EBV was detected by immunostaining for LMP1 and EBNA2 (Dako) and by ISH with EBV-encoded small RNA (EBER) probe. Immunohistochemistry and ISH were performed on an automated stainer (Benchmark XT; Ventana Medical Systems), in accordance with the manufacturer's recommendations. To determine the cell lineage of EBV-infected cells, paraffin sections were applied to double staining with EBER ISH and immunohistochemistry.
Detection of EBV-specific T cell response. Enzyme-linked immunospot (ELISPOT) assay was performed with the Immunocyto IFN-␥ ELISPOT Kit (MBL), in accordance with the instructions supplied by the manufacturer. Briefly, CD8 ϩ T cells were isolated from PBMCs from EBV-infected hNOG mice with the IMag anti-human CD8 Particles-DM (BD Biosciences). Mixture of these CD8 ϩ T cells and an autologous LCL were incubated with interleukin (IL)-2 in microplates coated with antibody to interferon (IFN)-␥ for 17 h. Captured IFN-␥ was detected by use of biotinated antibody to IFN-␥ and alkaline phosphatase-conjugated streptavidin and was visualized by reaction with the BCIP/NBT chromogen substrate. The unpaired Student's t test was used for statistical analysis. IFN-␥ secretion in response to EBV was also examined by flow cytometry, as described elsewhere [25] . Briefly, aliquots of murine splenocytes and an LCL were mixed in 6-well plates in the presence of brefeldin A (10 g/ mL) and incubated at 37°C in 5% CO 2 for 17 h. After incubation, the cell suspensions were stained with phycoerythrinconjugated anti-human CD69, phycoerythrin-Texas redconjugated anti-human CD45, and phycoerythrin-cyanin 5-conjugated anti-human CD8 for 30 min at 4°C and were fixed with 2% paraformaldehyde. Cells were then permeabilized and stained with BD Perm/Wash buffer (BD Biosciences) containing fluorescein isothiocyanate-conjugated anti-human IFN-␥ for 30 min at 4°C. Stained cells were analyzed using an EpicsXL flow cytometer (Beckman Coulter). Original magnifications, ϫ200 for all except EBER/CD20, which is ϫ400. E and F, Reverse-transcription polymerase chain reaction detection of latent-cycle (E) and lytic-cycle (F) EBV gene expression in tumors from EBV-infected hNOG mice. Spleen tumors from 3 different mice were examined for the expression of EBNA1, EBNA2, LMP1, LMP2A, LMP2B, EBER1, BZLF1, BMRF1, and BLLF1. RNA samples from a lymphoblastoid cell line (LCL) (E) and anti-IgG-treated Akata cells (F) were used as positive controls, and an RNA sample from EBV-negative Akata cells (E and F) was used as a negative control. Assays were done with (ϩ) or without (Ϫ) reverse transcriptase (RT) in panel F. Expression of GAPDH was examined as a reference. G, Double staining of EBER and CD20 in the liver of an hNOG mouse that was persistently infected with EBV without developing lymphoproliferative disorder. EBER is stained navy in the nucleus, and CD20 is stained brown in the membrane. Original magnification, ϫ1000.
Detection of antibodies specific to EBV. IgM antibody to the EBV BFRF3 protein was detected by immunoblotting essentially as described elsewhere [24] , except that horseradish peroxidase-conjugated antibody specific to human IgM (Beckman Coulter) was used as secondary antibody. To prepare the glutathione s-transferase (GST)-BFRF3 fusion protein, a DNA fragment spanning the entire coding region of BFRF3 was amplified by PCR (sense primer, 5'-GGCTCGAATTCATGGCACGCCG-GCTGCCC-3'; antisense primer, 5'-GGCTCGGATCCATAC-ACCATGTTTCGTGCCC-3') and inserted to the GST fusion vector pSGENT2, to yield the plasmid pSGENT2-BFRF3. Escherichia coli cells harboring pSGENT2-BFRF3 were stimulated with isopropyl ␤-D-1-thiogalactopyranoside to induce the expression of GST-BFRF3, which was subsequently purified by use of the Bulk GST Purification Module (GE Healthcare).
RESULTS

EBV infection in hNOG mice.
Transplantation of human CD34 ϩ HSCs in NOG mice and reconstitution of the human hematoimmune system were done as described elsewhere [18, 20] . In the initial attempts at infection, 1 ϫ 10 3 TD 50 of the Akata strain of EBV was inoculated into 6 hNOG mice, and EBV DNA was demonstrated in the peripheral blood of all of them (figure 1A). EBV DNA was first evident at 3-4 weeks after inoculation and reached peak levels of ϳ1 ϫ 10 6 EBV DNA copies/g of DNA. All 6 mice became seriously ill between 5 and 10 weeks after inoculation, with signs of weight loss ( figure 1A) , general inactivity, and piloerection. In contrast, EBV DNA was not detected in the peripheral blood, bone marrow, thymus, spleen, lymph nodes, liver, kidneys, and lungs of 3 control NOG mice that were not transplanted with HSCs but were inoculated with the virus (data not shown). Similarly, no signs of EBV infection were observed in 3 control hNOG mice that were not inoculated with the virus (data not shown). In total, 43 NOG mice that had been humanized with HSCs from 9 different cord blood samples were inoculated with 1 ϫ 10 3 TD 50 of EBV, and in 38 of them the results were similar to those observed in the initial 6 mice, with high blood EBV load and severe deterioration in their general condition. Ten of them died and could not be examined further. The remaining 28 mice were killed, and signs of lymphoproliferative disorder were found at autopsy (see the below). These results demonstrate that hNOG mice can be infected with EBV, with a mostly fatal outcome at this virus dose.
EBV-induced lymphoproliferative disorder in hNOG mice. Autopsy of killed mice showed signs of lymphoproliferative disorder typically represented by an overt tumor in the spleen (figure 2B) . In ϳ70% (20/28) of the mice autopsied, macroscopical signs of disseminated disease were found in the liver, lymph nodes, or kidneys ( figure 2A and 2B ). Seventeen mice were examined pathologically, and 15 of them showed typical histology of diffuse large B cell lymphoma, with remarkable similarity to the human lymphoproliferative disorder in the immunocompromised hosts ( figure 2C ). The tissues contained occasional immunoblasts, Reed-Sternberg-like cells, and Hodgkin-like cells ( figure 2C ). Marked infiltration of large transformed lymphoid cells was also demonstrated in liver, lymph nodes, kidneys, adrenal glands, and lungs ( figure 2C ). Real-time PCR detected high levels (ϳ1 ϫ 10 5 to ϳ1 ϫ 10 6 EBV DNA copies/g of DNA) of EBV DNA in these organs, and the large transformed lymphoid cells were universally EBV positive by EBER ISH (figure 2D) . Immunohistochemical analysis showed that the large transformed lymphoid cells were of the activated B cell phenotype, being reactive for CD20 and CD23 and not reactive for CD3 and CD10 (figure 2D and data not shown). They were also positive for Mum-1, a late-and postgerminal center cell marker. The EBER-positive cells were CD20-positive B cells (figure 2D), and no EBER-positive T cells were identified. Immunostaining revealed that most proliferating cells expressed EBNA2, whereas LMP1 was expressed in only a fraction of them ( figure 2D ). RT-PCR analysis of typical spleen tumors obtained from 3 different mice showed the expression of EBNA1, EBNA2, LMP1, LMP2A, LMP2B; and EBER, consistent with the latency III program of EBV gene expression ( figure 2E ). In addition, transcripts from lytic-cycle EBV genes, including BZLF1 (immediate-early), BMRF1 (early), and BLLF1 (late, encoding gp350/220), were identified ( figure 2F) .
Virus dose-dependent outcome of EBV infection in hNOG mice. To examine the influence of virus dose on the outcome of EBV infection, we inoculated serial dilutions of EBV preparation into 2 lots of hNOG mice, each consisting of 5 mice that had been humanized with the same HSC preparation. Consistent with the results described above, the 4 mice (2 from each lot) that received the higher doses (1 ϫ 10 3 and 1 ϫ 10 2 TD 50 ) of the virus died of lymphoproliferative disorder ϳ5-10 weeks after inoculation. The remaining mice in both of the lots that received lower doses (1 ϫ 10 1 , 1 ϫ 10 0 , and 1 ϫ 10 -1 TD 50 ) survived acute infection and appeared normal throughout the observation period of 22 weeks. Although EBV DNA was detected at variable levels in their peripheral blood several weeks after inoculation, it returned to undetectable levels thereafter (figure 1B), suggesting that a certain protection mechanism worked to control EBV infection. Importantly, EBV DNA could be still detected in various organs, including spleen, liver, lungs, kidneys, and adrenal glands, at the end of the observation period (22 weeks), indicating that EBV persisted in these mice (table 2) . Double staining for EBER and CD20 showed that EBV persisted in B cells (figure 2G). Macroscopical examination by autopsy at the end of the observation period did not reveal abnormality in these mice, except for moderate splenomegaly found in a mouse that received 1 ϫ 10 1 TD 50 . These results indicate that the outcome of EBV infection in hNOG mice varies with the virus dose; high doses of virus tend to cause fatal lymphoproliferative disorder, whereas lower doses induce apparently asymptomatic persistent infection.
EBV-specific T cell response in hNOG mice. Flow cytometry analysis demonstrated a dramatic increase in the percentage of CD3 ϩ T cells among the human CD45 ϩ leukocytes after infection with EBV. This increase in T cells was accompanied by an increase in the percentage of CD8 ϩ cells among human CD3 ϩ T cells. These changes were seen in virtually all infected mice, and the results from 3 mice are shown in figure 3A . The slow increase in the percentage of CD3 ϩ cells in the uninfected mouse represents the process of humanization (i.e., the development of hu- . CD8 ϩ cells isolated from EBV-infected hNOG mice were cocultured with an autologous LCL, and IFN-␥-secreting cells were counted (3, 5, 6, 7, and 8) . To analyze restriction by major histocompatibility complex (MHC), antibody to HLA class I (anti-human HLA-ABC clone W6/32; eBioscience) (5), antibodies to both HLA class I and class II (6), antibody to HLA class II (anti-human HLA-DP,DQ,DR clone CR3/43; Dako) (7), or isotype-matched control antibody (8) were added to the culture. Control experiments included coculture of CD8 ϩ cells with an MHC-mismatched LCL (1), culture of the autologous LCL only (2), and culture of CD8 ϩ cells only (4) . Results from 2 infected mice are shown. Five hundred CD8 ϩ cells per well were cultured in the experiment shown on the left, and 250 CD8 ϩ cells per well were cultured in that shown on the right. Spots were counted in triplicate in each of the 8 experimental groups, and the bars represent mean values and SEs. The unpaired Student's t test was used for statistical analysis. *P Ͻ .01 and **P Ͻ .02. B, Detection of human CD8 ϩ cells that produce IFN-␥ in response to stimulation with an EBV-positive LCL by flow cytometry. CD8 ϩ cells were isolated from the spleen of an EBV-infected mouse and cocultured with the autologous LCL. Intracellular IFN-␥ was stained and analyzed as described in Methods.
man T cells). This increase in CD8
ϩ cells were even more conspicuous when their definite number was counted ( figure 3B ). When hNOG mice were inoculated with serially diluted virus samples, a striking dose response was evident; mice inoculated with higher doses exhibited a more profound increase in CD8 ϩ cells at earlier time points ( figure 3C ). Further flow cytometry analyses showed that CD45RO ϩ memory T cells, compared with CD45RA ϩ T cells, increased in infected hNOG mice ( figure 3D ).
Expression of a T cell activation marker, HLA-DR, was observed mainly in CD8 ϩ cells rather than in CD4 ϩ cells ( figure 3D ).
To demonstrate that these CD8 ϩ T cells were directed against EBV-infected cells, we examined IFN-␥ secretion after stimulation with EBV-transformed cells. For this purpose, we first established an LCL using B cells isolated from the same cord blood that was used to isolate HSCs for transplantation. CD8 ϩ T cells, isolated from the peripheral blood of EBV-infected hNOG mice, were incubated with this autologous LCL, and cells secreting IFN-␥ were detected by ELISPOT assay. For all 3 EBV-infected hNOG mice (which had been infected at 1 ϫ 10 3 TD 50 ) thus examined, a significant number of spots were recognized in the wells in which CD8 ϩ T cells were mixed with the autologous LCL, whereas those cells incubated with unrelated LCL had many fewer spots (data from 2 mice are shown in figure 4A ). CD8 ϩ T cells isolated from uninfected hNOG mice did not give a significant number of spots (data not shown). Release of IFN-␥ was blocked by antibody specific to human major histocompatibility complex (MHC) class I but not by that specific to human MHC class II ( figure 4A ). These results clearly show that a T cell response restricted by human MHC class I was mounted against EBV-infected cells. In addition, in 5 of the 6 EBV-infected hNOG mice examined (infected at 1 ϫ 10 3 TD 50 ), flow cytometry also demonstrated production of IFN-␥ by CD8 ϩ T cells isolated from the spleen and stimulated with an autologous LCL ( figure 4B ). EBV-specific antibody response in hNOG mice. Serum samples from 30 EBV-infected hNOG mice were examined by Western blotting for IgM antibodies reactive with a bacterially expressed GST-BFRF3 fusion protein. The BFRF3 protein is a major component of the virus capsid antigen of EBV [26] . The results are shown in figure 5A and indicated that four serum samples (from mice infected at 1 ϫ 10 1 or 1 ϫ 10 3 TD 50 ) contained IgM antibody reactive with it. These serum samples reacted also with the 18-kDa BFRF3-encoded protein in the lysate of Akata cells stimulated with IgG antibody to activate virus production (figure 5B). Similar experiments with human IgG-specific secondary antibody did not show a positive reaction with either GST-BFRF or p18 BFRF3 . Six serum samples collected from uninfected hNOG mice reacted with neither the 18-kDa protein nor GST-BFRF3 (figure 5 and data not shown). These results indicate that hNOG mice have the ability to mount an IgM response to EBV.
DISCUSSION
The lymphoproliferative disease induced in hNOG mice is remarkably similar to the human lymphoproliferative disorder seen in immunocompromised hosts [27] with respect to histology, surface phenotype, and the type of EBV gene expression (latency III). Reproduction of latency III in the present study makes for an interesting contrast with the previous model using NOD/scid mice, which exhibited the latency II pattern [10] .
EBV infection in lower doses resulted in a transient increase in EBV DNA load in the peripheral blood, followed by apparently asymptomatic infection that persisted for at least 22 weeks. This type of asymptomatic EBV infection has not been described in nonprimate models of EBV infection and may be regarded as a model of human EBV latency. To compare this condition in NOG mice with EBV latency in humans precisely, we need to further investigate the nature of host cells (i.e., whether they are memory B cells), the pattern of EBV gene expression in them, and the involvement of anti-EBV immune responses in its maintenance.
In hNOG mice, human T cells develop in thymus tissue, in which epithelial cells are of murine origin [16] . It is therefore interesting that they could mount a T cell response restricted by human MHC class I. Although this suggests that positive selection of human T cells occurred in hNOG mice, the mechanism of T cell education remains unclear. Alloantigen-specific and human MHC class I-restricted T cell cytotoxicity has been reported in hNOG mice [15, 16] . An EBV-induced T cell response was evident in mice that received high doses of virus and developed lymphoproliferative disorder, suggesting that the T cell response in hNOG mice was not sufficient to control EBV-induced lymphoproliferation when they were infected at high doses. That only a minor fraction of CD8 ϩ T cells appeared to be EBV specific, as evidenced by ELISPOT assay and flow cytometry, may explain this result, at least partially. A humoral immune response to EBV has not been documented in previous mouse models of EBV infection, and therefore the NOG mouse may provide a valuable tool to analyze the mechanism and the protective roles of antibody response in EBV infection. We have to date clearly identified only IgM antibody to the 18-kDa component of virus capsid antigen in a minor fraction (4/30) of infected mice. We are currently attempting to improve sensitivity and to see whether hNOG mice can mount a more efficient and divergent antibody response to the virus, possibly including the production of IgG antibodies. Because both the T cell-mediated and the humoral immune response are elicited in hNOG mice, they may be useful in the evaluation of candidate EBV vaccines.
Very recently, humanized mice based on other immunodeficient mouse strains were prepared, and EBV was used as a typical pathogen to analyze their immune functions. Traggiai et al. [12] infected humanized Rag2 Ϫ/Ϫ IL-2R␥ Ϫ/Ϫ mice with EBV and documented an in vitro proliferative response by CD8 ϩ T cells to an autologous LCL. Melkus et al. [11] , on the other hand, humanized NOD/scid mice by transplanting human fetal liver, thymus, and HSCs and succeeded in inducing an EBV-specific T cell immune response as well as an innate immune response to toxic shock syndrome toxin 1. These 2 studies were performed mainly using immunological standpoints and did not provide detailed data from virological investigations. An advantage of the NOG mouse model described here is that it does not require a fine surgical procedure using human fetal tissue; therefore, NOG mice can be easily provided in large quantities. In immunocompromised humans, failure of immunosurveillance may lead to the development of lymphoproliferative disorder. We expect that the NOG mouse model can be used to analyze the exact relationship between immunodeficiency and the development of lymphoproliferative disorder. Immune responses in the hNOG mouse can be modulated by immunosuppressive drugs (such as cyclosporine A) or HIV, and the development of lymphoproliferative disorder can be analyzed with special reference to the nature and level of immunodeficiency. This kind of study, which has not been possible with conventional scid mice, may reveal an exact condition in which lymphoproliferative disorder develops and may thereby aid the development of a specified immunosuppressive procedure that evades this condition and precludes the risk of lymphoproliferative disorder.
In summary, the NOG mouse is able to recapitulate various essential elements of human EBV infection and is therefore, to our knowledge, the most comprehensive small-animal model of EBV infection described to date. It should be a valuable tool for the study of the pathogenesis, prevention, and treatment of EBV infection.
